Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (DE:CN2)
FRANKFURT:CN2
Catalyst Pharma (CN2) Ownership - Who Owns Catalyst Pharma?
3 Followers
Catalyst Pharma (CN2) Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.68% Other Institutional Investors
99.32% Public Companies and
Individual Investors
The ownership structure of Catalyst Pharma (DE:CN2) stock is a mix of institutional, retail and individual investors. Approximately 0.68% of the company’s stock is owned by Institutional Investors, 0.00% is owned by Insiders and 99.32% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
| Apr 10, 2024 | David Tierney Director | Sold | $392000 |
| Apr 10, 2024 | David Tierney Director | Bought | $100250 |
| Mar 28, 2024 | Brian Elsbernd Chief Compliance/legal Officer | Sold | $411000 |
| Feb 06, 2024 | Donald Denkhaus Director | Bought | $160400 |
Recent Hedge Fund Trading Activity
Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2023 | Bought | $184 | |
| Dec 31, 2023 | Bought | $1966 | |
| Dec 31, 2023 | Sold | $244770 | |
| Dec 31, 2023 | Sold | $630408 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,528,256 | Insider | ― | 61,176,739 | |
| 44,700 | Insider | ― | 603,897 | |
| 438,333 | Insider | ― | 5,921,879 | |
| 204,887 | Insider | ― | 2,768,023 | |
| 212,147 | Insider | ― | 2,866,106 | |
| 825,124 | Insider | ― | 11,147,425 | |
| 55,813 | Insider | ― | 754,034 | |
| 348,874 | Insider | ― | 4,713,288 | |
| 51,391 | Insider | ― | 694,292 | |
| 134,131 | Insider | ― | 1,812,110 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 139,547 | Institution | ― | 2,017,710 | |
| 7 | Institution | ― | 101 | |
| 21,724 | Institution | ― | 314,107 | |
| 157,609 | Institution | ― | 2,278,869 | |
| 7,866 | Institution | ― | 113,734 | |
| 661,359 | Institution | ― | 9,562,590 | |
| 360,771 | Institution | ― | 5,216,388 | |
| 38,798 | Institution | ― | 560,980 | |
| 113,111 | Institution | ― | 1,635,472 | |
| 5,200 | Institution | ― | 75,187 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|
FAQ
Who Owns Catalyst Pharma (DE:CN2)?
According to the latest TipRanks data, approximately 0.68% of the company's stock is held by institutional investors, 0.00% is held by insiders, and 99.32% is held by retail investors.
What percentage of Catalyst Pharma (DE:CN2) stock is held by institutional investors?
According to the latest TipRanks data, approximately 0.68% of Catalyst Pharma (DE:CN2) stock is held by institutional investors.
What percentage of Catalyst Pharma (DE:CN2) stock is held by retail investors?
According to the latest TipRanks data, approximately 99.32% of Catalyst Pharma (DE:CN2) stock is held by retail investors.
Who owns the most shares of Catalyst Pharma (DE:CN2)?
Patrick Mcenany owns the most shares of Catalyst Pharma (DE:CN2).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.